相关实验视频

Updated: Jun 25, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

准TUBB3抑制了阿诺基斯的抵抗力和前列腺癌中的骨转移

Bingqi Dong¹, Yanlun Gu^2,3,4, Xiaojiao Sun^4,5

¹Department of General Surgery, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing, 100034, China.

Advanced healthcare materials

|May 29, 2024

概括

准TUBB3,一个驱动前列腺癌 (PCa) 抗性基因,显著抑制骨转移. 提供siTUBB3的新型骨定位纳米粒子为先进的PCa提供了有前途的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物技术是生物技术.

背景情况:

骨转移在晚期前列腺癌 (PCa) 中普遍存在,显著恶化患者的预后.
阿诺基的抗性,即癌细胞在脱落后生存的能力,是瘤转移的关键因素.
针对阿诺基的抗药性,为对抗转移性传播提供了重要的治疗机会.

研究的目的:

识别调节PCa中阿诺基斯抗性的关键基因,并评估它们的治疗潜力.
调查TUBB3在PCa骨转移和阿诺基斯抗性的作用.
开发和评估一种新的向性输送系统,用于治疗骨转移性PCa的治疗干预.

主要方法:

为PCa.开发一种与anoikis相关的预后风险模型.
对PCa细胞中的TUBB3表达的分析及其与anoikis抗性,侵入性,迁移性和上皮-介质细胞过渡 (EMT) 的相关性.
在PCa骨转移模型中,创建骨向脂纳米粒子 (BT-LNP) 用于siRNA输送 (siTUBB3) 和体内评估.

主要成果:

TUBB3被确定为关键的阿诺基斯相关基因,在骨转移PCa中高度表达,与阿诺基斯耐药性相关.
TUBB3的枯竭逆转了阿诺基斯的抵抗力,抑制了PCa细胞的入侵,迁移和EMT,并减少了αvβ3/FAK/Src轴的激活.
在体内,BT-LNP介导的siTUBB3系统输送有效地减弱了PCa骨转移的进展.

结论:

TUBB3是阿诺基斯抗性的关键调节者,也是骨转移性PCa.的可行的治疗点.
通过BT-LNP介导的siTUBB3输送是一种新且有效的治疗策略,用于治疗PCa骨转移.

关键词:

在 TUBB3 管道上.骨微环境是一个微环境.整体的整体是整体的脂质纳米颗粒是一种纳米粒子.前列腺癌是前列腺癌.

更多相关视频

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...